[10-Q] Harvard Bioscience Inc Quarterly Earnings Report
Harvard Bioscience reported weaker sales and a large non-cash charge that materially worsened results for the six months. Revenue declined to $20.45 million in the quarter (down ~11.5% year-over-year) and to $42.22 million for the six-month period (down ~11.3%). The company recorded a $47.951 million goodwill impairment that drove a six-month net loss of $52.622 million (loss per share $1.19). Operating cash flow improved, providing $5.741 million for the six months, and cash and cash equivalents rose to $7.442 million from $4.108 million.
The balance sheet shows $34.864 million of debt (term loan $22.7 million; revolver $12.65 million) and continued covenant pressure. Management obtained a covenant waiver in August 2025 conditioned on completing a refinancing by December 2025, creating substantial doubt about the company’s ability to continue as a going concern unless refinancing or other capital is secured. The filing also discloses previously reported material weaknesses in internal controls that remain under remediation.
Harvard Bioscience ha riportato vendite più deboli e un rilevante addebito non monetario che ha peggiorato significativamente i risultati nei sei mesi. I ricavi sono scesi a $20.45 milioni nel trimestre (in calo di circa l'11,5% su base annua) e a $42.22 milioni nei sei mesi (in calo di circa l'11,3%). La società ha registrato una svalutazione dell'avviamento pari a $47.951 milioni che ha determinato una perdita netta semestrale di $52.622 milioni (perdita per azione $1,19). Il flusso di cassa operativo è migliorato, generando $5.741 milioni nei sei mesi, e la liquidità e disponibilità liquide sono aumentate a $7.442 milioni da $4.108 milioni.
Lo stato patrimoniale evidenzia un indebitamento di $34.864 milioni (prestito a termine $22.7 milioni; linea di credito revolving $12.65 milioni) e una continua pressione sui covenant. La direzione ha ottenuto ad agosto 2025 una deroga ai covenant condizionata al completamento di un rifinanziamento entro dicembre 2025, il che crea dubbi sostanziali sulla capacità dell'azienda di continuare come ente in funzionamento a meno che non si assicuri il rifinanziamento o altro capitale. Il documento segnala inoltre carenze significative nei controlli interni già precedentemente riportate e tuttora in fase di rimedio.
Harvard Bioscience informó ventas más débiles y un cargo no monetario importante que deterioró de manera significativa los resultados del semestre. Los ingresos cayeron a $20.45 millones en el trimestre (aprox. -11.5% interanual) y a $42.22 millones en el periodo de seis meses (aprox. -11.3%). La compañía registró un deterioro del goodwill de $47.951 millones que provocó una pérdida neta semestral de $52.622 millones (pérdida por acción $1.19). El flujo de caja operativo mejoró, aportando $5.741 millones en seis meses, y el efectivo y equivalentes de efectivo aumentaron a $7.442 millones desde $4.108 millones.
El balance muestra $34.864 millones de deuda (préstamo a plazo $22.7 millones; línea revolvente $12.65 millones) y persistente presión sobre los covenants. La dirección obtuvo en agosto de 2025 una exención de covenant condicionada a completar un refinanciamiento antes de diciembre de 2025, lo que genera dudas sustanciales sobre la capacidad de la empresa para seguir como negocio en marcha a menos que se asegure el refinanciamiento u otro capital. La presentación también divulga debilidades materiales en los controles internos ya informadas y que siguen en proceso de remediación.
하버드 바이오사이언스는 매출이 약화되고 비현금성 비용이 크게 반영되어 반기 실적이 크게 악화되었다고 보고했습니다. 분기 매출은 $20.45백만(전년 대비 약 11.5% 감소), 반기 매출은 $42.22백만(전년 대비 약 11.3% 감소)으로 감소했습니다. 회사는 $47.951백만의 영업권 손상차손을 계상해 반기 순손실이 $52.622백만(주당 손실 $1.19)을 기록했습니다. 영업현금흐름은 개선되어 반기 동안 $5.741백만을 창출했고, 현금 및 현금성자산은 $4.108백만에서 $7.442백만으로 늘어났습니다.
대차대조표에는 $34.864백만의 부채(기한부 대출 $22.7백만; 리볼빙(회전) 신용 $12.65백만)가 기재되어 있으며 covenant(약정)에 대한 압박이 계속되고 있습니다. 경영진은 2025년 8월에 계정 약정에 대한 유예를 받았으나 이는 2025년 12월까지 리파이낸싱을 완료하는 것을 조건으로 하고 있어, 리파이낸싱이나 다른 자본 확보가 이루어지지 않으면 계속기업으로서의 존속 가능성에 중대한 의문을 제기합니다. 공시에는 이미 보고된 내부 통제의 중대한 결함이 여전히 시정 중이라는 점도 밝혀져 있습니다.
Harvard Bioscience a annoncé des ventes plus faibles et une charge non monétaire importante qui ont significativement dégradé les résultats semestriels. Le chiffre d'affaires est tombé à $20,45 millions au trimestre (en baisse d'environ 11,5% en glissement annuel) et à $42,22 millions pour les six mois (en baisse d'environ 11,3%). La société a enregistré une dépréciation du goodwill de $47,951 millions, entraînant une perte nette semestrielle de $52,622 millions (perte par action $1,19). Les flux de trésorerie d'exploitation se sont améliorés, fournissant $5,741 millions sur six mois, et la trésorerie et équivalents de trésorerie sont passés de $4,108 millions à $7,442 millions.
Le bilan fait apparaître une dette de $34,864 millions (prêt à terme $22,7 millions ; ligne de crédit renouvelable $12,65 millions) et une pression continue sur les covenants. La direction a obtenu en août 2025 une dérogation conditionnée à la réalisation d'un refinancement d'ici décembre 2025, ce qui soulève des doutes importants quant à la capacité de l'entreprise à poursuivre son exploitation sauf en cas d'obtention d'un refinancement ou d'autres capitaux. Le dépôt révèle également des faiblesses importantes des contrôles internes déjà signalées et toujours en cours de remédiation.
Harvard Bioscience meldete schwächere Umsätze und einen großen nicht zahlungswirksamen Posten, der die Halbjahresergebnisse deutlich verschlechterte. Der Umsatz sank im Quartal auf $20,45 Mio. (ca. -11,5% gegenüber dem Vorjahr) und im Halbjahr auf $42,22 Mio. (ca. -11,3%). Das Unternehmen verbuchte eine Goodwill-Abwertung in Höhe von $47,951 Mio., die zu einem Nettoverlust für das Halbjahr von $52,622 Mio. (Verlust je Aktie $1,19) führte. Der operative Cashflow verbesserte sich und lieferte $5,741 Mio. für das Halbjahr, und liquide Mittel stiegen von $4,108 Mio. auf $7,442 Mio.
Die Bilanz weist Verbindlichkeiten von $34,864 Mio. aus (Tilgungsdarlehen $22,7 Mio.; revolvierende Kreditlinie $12,65 Mio.) und weiterhin Druck auf die Covenants. Das Management erhielt im August 2025 eine Waiver von den Covenants, die an die Bedingung geknüpft ist, bis Dezember 2025 ein Refinanzierung abzuschließen, was erhebliche Zweifel an der Fortführungsfähigkeit des Unternehmens aufwirft, sofern keine Refinanzierung oder sonstige Kapitalbeschaffung gelingt. Die Einreichung offenlegt außerdem zuvor berichtete wesentliche Mängel in den internen Kontrollen, die noch behoben werden.
- None.
- None.
Insights
TL;DR: Revenue softness and a $48.0M goodwill write-down produced a large six-month loss, reducing equity and triggering heightened investor risk.
The company reported sequential and year-over-year revenue declines (quarter: $20.45M versus $23.10M) and a $47.951M goodwill impairment recorded in the first half, which accounted for the majority of the $52.622M six-month net loss. Gross margin contracted modestly to ~56% driven by lower absorption of fixed manufacturing costs and a higher mix of lower-margin products. While operating expense reductions helped limit operating losses in the quarter, the impairment and accumulated deficit (now $(210.6)M) materially weaken equity metrics. This combination is likely to weigh on valuation and credit metrics absent clear improvement in top-line trends or a successful refinancing.
TL;DR: Cash and operating cash flow improved, but debt covenants, increased interest margins, and a refinancing deadline create acute liquidity risk.
Cash rose to $7.442M and net cash from operations was $5.741M for the six months, aided by $5.4M of employee retention tax credit refunds recognized to date. Total debt outstanding was $34.864M with a term loan balloon due December 2025 and the revolver capped. Lenders agreed to an August 2025 waiver conditioned on pursuing refinancing by December 2025 and increased the interest margin to SOFR+700bps under that amendment. Failure to refinance would constitute an event of default and could accelerate repayment, so near-term access to capital is a critical operational constraint.
Harvard Bioscience ha riportato vendite più deboli e un rilevante addebito non monetario che ha peggiorato significativamente i risultati nei sei mesi. I ricavi sono scesi a $20.45 milioni nel trimestre (in calo di circa l'11,5% su base annua) e a $42.22 milioni nei sei mesi (in calo di circa l'11,3%). La società ha registrato una svalutazione dell'avviamento pari a $47.951 milioni che ha determinato una perdita netta semestrale di $52.622 milioni (perdita per azione $1,19). Il flusso di cassa operativo è migliorato, generando $5.741 milioni nei sei mesi, e la liquidità e disponibilità liquide sono aumentate a $7.442 milioni da $4.108 milioni.
Lo stato patrimoniale evidenzia un indebitamento di $34.864 milioni (prestito a termine $22.7 milioni; linea di credito revolving $12.65 milioni) e una continua pressione sui covenant. La direzione ha ottenuto ad agosto 2025 una deroga ai covenant condizionata al completamento di un rifinanziamento entro dicembre 2025, il che crea dubbi sostanziali sulla capacità dell'azienda di continuare come ente in funzionamento a meno che non si assicuri il rifinanziamento o altro capitale. Il documento segnala inoltre carenze significative nei controlli interni già precedentemente riportate e tuttora in fase di rimedio.
Harvard Bioscience informó ventas más débiles y un cargo no monetario importante que deterioró de manera significativa los resultados del semestre. Los ingresos cayeron a $20.45 millones en el trimestre (aprox. -11.5% interanual) y a $42.22 millones en el periodo de seis meses (aprox. -11.3%). La compañía registró un deterioro del goodwill de $47.951 millones que provocó una pérdida neta semestral de $52.622 millones (pérdida por acción $1.19). El flujo de caja operativo mejoró, aportando $5.741 millones en seis meses, y el efectivo y equivalentes de efectivo aumentaron a $7.442 millones desde $4.108 millones.
El balance muestra $34.864 millones de deuda (préstamo a plazo $22.7 millones; línea revolvente $12.65 millones) y persistente presión sobre los covenants. La dirección obtuvo en agosto de 2025 una exención de covenant condicionada a completar un refinanciamiento antes de diciembre de 2025, lo que genera dudas sustanciales sobre la capacidad de la empresa para seguir como negocio en marcha a menos que se asegure el refinanciamiento u otro capital. La presentación también divulga debilidades materiales en los controles internos ya informadas y que siguen en proceso de remediación.
하버드 바이오사이언스는 매출이 약화되고 비현금성 비용이 크게 반영되어 반기 실적이 크게 악화되었다고 보고했습니다. 분기 매출은 $20.45백만(전년 대비 약 11.5% 감소), 반기 매출은 $42.22백만(전년 대비 약 11.3% 감소)으로 감소했습니다. 회사는 $47.951백만의 영업권 손상차손을 계상해 반기 순손실이 $52.622백만(주당 손실 $1.19)을 기록했습니다. 영업현금흐름은 개선되어 반기 동안 $5.741백만을 창출했고, 현금 및 현금성자산은 $4.108백만에서 $7.442백만으로 늘어났습니다.
대차대조표에는 $34.864백만의 부채(기한부 대출 $22.7백만; 리볼빙(회전) 신용 $12.65백만)가 기재되어 있으며 covenant(약정)에 대한 압박이 계속되고 있습니다. 경영진은 2025년 8월에 계정 약정에 대한 유예를 받았으나 이는 2025년 12월까지 리파이낸싱을 완료하는 것을 조건으로 하고 있어, 리파이낸싱이나 다른 자본 확보가 이루어지지 않으면 계속기업으로서의 존속 가능성에 중대한 의문을 제기합니다. 공시에는 이미 보고된 내부 통제의 중대한 결함이 여전히 시정 중이라는 점도 밝혀져 있습니다.
Harvard Bioscience a annoncé des ventes plus faibles et une charge non monétaire importante qui ont significativement dégradé les résultats semestriels. Le chiffre d'affaires est tombé à $20,45 millions au trimestre (en baisse d'environ 11,5% en glissement annuel) et à $42,22 millions pour les six mois (en baisse d'environ 11,3%). La société a enregistré une dépréciation du goodwill de $47,951 millions, entraînant une perte nette semestrielle de $52,622 millions (perte par action $1,19). Les flux de trésorerie d'exploitation se sont améliorés, fournissant $5,741 millions sur six mois, et la trésorerie et équivalents de trésorerie sont passés de $4,108 millions à $7,442 millions.
Le bilan fait apparaître une dette de $34,864 millions (prêt à terme $22,7 millions ; ligne de crédit renouvelable $12,65 millions) et une pression continue sur les covenants. La direction a obtenu en août 2025 une dérogation conditionnée à la réalisation d'un refinancement d'ici décembre 2025, ce qui soulève des doutes importants quant à la capacité de l'entreprise à poursuivre son exploitation sauf en cas d'obtention d'un refinancement ou d'autres capitaux. Le dépôt révèle également des faiblesses importantes des contrôles internes déjà signalées et toujours en cours de remédiation.
Harvard Bioscience meldete schwächere Umsätze und einen großen nicht zahlungswirksamen Posten, der die Halbjahresergebnisse deutlich verschlechterte. Der Umsatz sank im Quartal auf $20,45 Mio. (ca. -11,5% gegenüber dem Vorjahr) und im Halbjahr auf $42,22 Mio. (ca. -11,3%). Das Unternehmen verbuchte eine Goodwill-Abwertung in Höhe von $47,951 Mio., die zu einem Nettoverlust für das Halbjahr von $52,622 Mio. (Verlust je Aktie $1,19) führte. Der operative Cashflow verbesserte sich und lieferte $5,741 Mio. für das Halbjahr, und liquide Mittel stiegen von $4,108 Mio. auf $7,442 Mio.
Die Bilanz weist Verbindlichkeiten von $34,864 Mio. aus (Tilgungsdarlehen $22,7 Mio.; revolvierende Kreditlinie $12,65 Mio.) und weiterhin Druck auf die Covenants. Das Management erhielt im August 2025 eine Waiver von den Covenants, die an die Bedingung geknüpft ist, bis Dezember 2025 ein Refinanzierung abzuschließen, was erhebliche Zweifel an der Fortführungsfähigkeit des Unternehmens aufwirft, sofern keine Refinanzierung oder sonstige Kapitalbeschaffung gelingt. Die Einreichung offenlegt außerdem zuvor berichtete wesentliche Mängel in den internen Kontrollen, die noch behoben werden.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
FORM
For the quarterly period ended
For the transition period from to
Commission file number
|
|
|
(Exact Name of Registrant as Specified in Its Charter) |
|
|
|
|
(State or other jurisdiction of Incorporation or organization) |
(I.R.S. Employer Identification No.) |
|
|
|
(Address of Principal Executive Offices, including zip code) |
|
( |
|
(Registrant’s telephone number, including area code) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
|
|
The |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S- T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer ☐ |
|
|
Non-accelerated filer ☐ |
Smaller reporting company |
|
Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
As of August 4, 2025, there were
HARVARD BIOSCIENCE, INC.
FORM 10-Q
INDEX
|
Page |
|
|
PART I - FINANCIAL INFORMATION |
1 |
|
Item 1. Financial Statements (Unaudited) |
1 |
|
Condensed Consolidated Balance Sheets |
1 |
|
Condensed Consolidated Statements of Operations |
2 |
|
Condensed Consolidated Statements of Comprehensive Loss |
3 |
|
Condensed Consolidated Statements of Stockholders' Equity |
4 |
|
Condensed Consolidated Statements of Cash Flows |
5 |
|
Notes to Condensed Consolidated Financial Statements |
6 |
|
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations |
18 |
|
Item 3. Quantitative and Qualitative Disclosures about Market Risk |
24 |
|
Item 4. Controls and Procedures |
24 |
|
PART II - OTHER INFORMATION |
25 |
|
Item 1. Legal Proceedings |
25 |
|
Item1A. Risk Factors |
25 |
|
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds |
26 |
|
Item 3. Defaults Upon Senior Securities |
26 |
|
Item 4. Mine Safety Disclosures |
26 |
|
Item 5. Other Information |
26 |
|
Item 6. Exhibits |
27 |
|
SIGNATURES |
28 |
PART I. FINANCIAL INFORMATION
|
Item 1. |
Financial Statements. |
HARVARD BIOSCIENCE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands, except share and per share data)
|
June 30, |
December 31, |
|||||||
|
2025 |
2024 |
|||||||
|
Assets |
||||||||
|
Current assets: |
||||||||
|
Cash and cash equivalents |
$ | $ | ||||||
|
Accounts receivable, net |
||||||||
|
Inventories |
||||||||
|
Other current assets |
||||||||
|
Total current assets |
||||||||
|
Property, plant and equipment, net |
||||||||
|
Operating lease right-of-use assets |
||||||||
|
Goodwill |
||||||||
|
Intangible assets, net |
||||||||
|
Other long-term assets |
||||||||
|
Total assets |
$ | $ | ||||||
|
Liabilities and Stockholders' Equity |
||||||||
|
Current liabilities: |
||||||||
|
Debt |
$ | $ | ||||||
|
Accounts payable |
||||||||
|
Contract liabilities |
||||||||
|
Other current liabilities |
||||||||
|
Total current liabilities |
||||||||
|
Deferred tax liability |
||||||||
|
Operating lease liabilities |
||||||||
|
Other long-term liabilities |
||||||||
|
Total liabilities |
||||||||
|
Commitments and contingencies - Note 13 |
|
|
||||||
|
Stockholders' equity: |
||||||||
|
Preferred stock, par value $ |
||||||||
|
Common stock, par value $ |
||||||||
|
Additional paid-in-capital |
||||||||
|
Accumulated deficit |
( |
) | ( |
) | ||||
|
Accumulated other comprehensive loss |
( |
) | ( |
) | ||||
|
Total stockholders' equity |
||||||||
|
Total liabilities and stockholders' equity |
$ | $ | ||||||
See accompanying notes to condensed consolidated financial statements.
HARVARD BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands, except per share data)
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
|
2025 |
2024 |
2025 |
2024 |
|||||||||||||
|
Revenues |
$ | $ | $ | $ | ||||||||||||
|
Cost of revenues |
||||||||||||||||
|
Gross profit |
||||||||||||||||
|
Sales and marketing expenses |
||||||||||||||||
|
General and administrative expenses |
||||||||||||||||
|
Research and development expenses |
||||||||||||||||
|
Amortization of acquired intangible assets |
||||||||||||||||
|
Goodwill impairment - Note 4 |
||||||||||||||||
|
Other operating expenses - Note 1 |
||||||||||||||||
|
Total operating expenses |
||||||||||||||||
|
Operating loss |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Other expense: |
||||||||||||||||
|
Interest expense |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Loss on equity securities - Note 6 |
( |
) | ( |
) | ||||||||||||
|
Other expense, net |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Total other expense |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Loss before income taxes |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Income tax expense (benefit) |
( |
) | ( |
) | ( |
) | ||||||||||
|
Net loss |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
Loss per share: |
||||||||||||||||
|
Basic and diluted loss per share |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
Weighted-average common shares: |
||||||||||||||||
|
Basic and diluted |
||||||||||||||||
See accompanying notes to condensed consolidated financial statements.
HARVARD BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited, in thousands)
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
|
2025 |
2024 |
2025 |
2024 |
|||||||||||||
|
Net loss |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
Other comprehensive income (loss), net of tax: |
||||||||||||||||
|
Foreign currency translation adjustments |
( |
) | ( |
) | ||||||||||||
|
Derivative instruments qualifying as cash flow hedges, net of tax of $- |
||||||||||||||||
|
Other comprehensive income (loss) |
( |
) | ( |
) | ||||||||||||
|
Comprehensive income (loss) |
$ | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||||
See accompanying notes to condensed consolidated financial statements.
HARVARD BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Unaudited, in thousands)
|
Accumulated |
||||||||||||||||||||||||
|
Number |
Additional |
Other |
Total |
|||||||||||||||||||||
|
of Shares |
Common |
Paid-in |
Accumulated |
Comprehensive |
Stockholders’ |
|||||||||||||||||||
|
Issued |
Stock |
Capital |
Deficit |
Loss |
Equity |
|||||||||||||||||||
|
Balance at March 31, 2025 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||
|
Stock purchase plan |
||||||||||||||||||||||||
|
Vesting of restricted stock units |
||||||||||||||||||||||||
|
Shares withheld for taxes |
( |
) | ||||||||||||||||||||||
|
Stock-based compensation |
- | |||||||||||||||||||||||
|
Net loss |
- | ( |
) | ( |
) | |||||||||||||||||||
|
Other comprehensive loss |
- | |||||||||||||||||||||||
|
Balance at June 30, 2025 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||
|
Accumulated |
||||||||||||||||||||||||
|
Number |
Additional |
Other |
Total |
|||||||||||||||||||||
|
of Shares |
Common |
Paid-in |
Accumulated |
Comprehensive |
Stockholders’ |
|||||||||||||||||||
|
Issued |
Stock |
Capital |
Deficit |
Loss |
Equity |
|||||||||||||||||||
|
Balance at March 31, 2024 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||
|
Stock option exercises |
||||||||||||||||||||||||
|
Stock purchase plan |
||||||||||||||||||||||||
|
Vesting of restricted stock units |
||||||||||||||||||||||||
|
Shares withheld for taxes |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
Stock-based compensation |
- | |||||||||||||||||||||||
|
Net loss |
- | ( |
) | ( |
) | |||||||||||||||||||
|
Other comprehensive loss |
- | ( |
) | ( |
) | |||||||||||||||||||
|
Balance at June 30, 2024 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||
|
Accumulated |
||||||||||||||||||||||||
|
Number |
Additional |
Other |
Total |
|||||||||||||||||||||
|
of Shares |
Common |
Paid-in |
Accumulated |
Comprehensive |
Stockholders’ |
|||||||||||||||||||
|
Issued |
Stock |
Capital |
Deficit |
Loss |
Equity |
|||||||||||||||||||
|
Balance at December 31, 2024 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||
|
Stock purchase plan |
||||||||||||||||||||||||
|
Vesting of restricted stock units |
||||||||||||||||||||||||
|
Shares withheld for taxes |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
Stock-based compensation |
- | |||||||||||||||||||||||
|
Net loss |
- | ( |
) | ( |
) | |||||||||||||||||||
|
Other comprehensive loss |
- | |||||||||||||||||||||||
|
Balance at June 30, 2025 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||
|
Accumulated |
||||||||||||||||||||||||
|
Number |
Additional |
Other |
Total |
|||||||||||||||||||||
|
of Shares |
Common |
Paid-in |
Accumulated |
Comprehensive |
Stockholders’ |
|||||||||||||||||||
|
Issued |
Stock |
Capital |
Deficit |
Loss |
Equity |
|||||||||||||||||||
|
Balance at December 31, 2023 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||
|
Stock option exercises |
||||||||||||||||||||||||
|
Stock purchase plan |
||||||||||||||||||||||||
|
Vesting of restricted stock units |
||||||||||||||||||||||||
|
Shares withheld for taxes |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
Stock-based compensation |
- | |||||||||||||||||||||||
|
Net loss |
- | ( |
) | ( |
) | |||||||||||||||||||
|
Other comprehensive loss |
- | ( |
) | ( |
) | |||||||||||||||||||
|
Balance at June 30, 2024 |
( |
) | ( |
) | ||||||||||||||||||||
See accompanying notes to condensed consolidated financial statements
HARVARD BIOSCIENCE, INC.
Condensed Consolidated Statements Of Cash Flows
(Unaudited, in thousands)
|
Six Months Ended June 30, |
||||||||
|
2025 |
2024 |
|||||||
|
Cash flows from operating activities: |
||||||||
|
Net loss |
$ | ( |
) | $ | ( |
) | ||
|
Adjustments to reconcile net loss to net cash provided by operating activities: |
||||||||
|
Depreciation |
||||||||
|
Amortization of intangible assets |
||||||||
|
Goodwill impairment - Note 4 |
||||||||
|
Amortization of deferred financing costs |
||||||||
|
Stock-based compensation |
||||||||
|
Deferred income taxes and other |
( |
) | ||||||
|
Loss on equity securities - Note 6 |
||||||||
|
Changes in operating assets and liabilities: |
||||||||
|
Accounts receivable |
||||||||
|
Inventories |
( |
) | ||||||
|
Other assets |
( |
) | ||||||
|
Accounts payable and other liabilities |
( |
) | ||||||
|
Contract liabilities |
( |
) | ( |
) | ||||
|
Net cash provided by operating activities |
||||||||
|
Cash flows from investing activities: |
||||||||
|
Additions to property, plant and equipment |
( |
) | ( |
) | ||||
|
Capitalized software development costs |
( |
) | ( |
) | ||||
|
Proceeds from sale of marketable equity securities |
||||||||
|
Net cash (used in) provided by investing activities |
( |
) | ||||||
|
Cash flows from financing activities: |
||||||||
|
Borrowing from revolving line of credit |
||||||||
|
Repayment of revolving line of credit |
( |
) | ||||||
|
Repayment of term debt |
( |
) | ( |
) | ||||
|
Payment of debt issuance costs |
( |
) | ||||||
|
Proceeds from exercise of stock options and employee stock purchase plan |
||||||||
|
Taxes paid related to net share settlement of equity awards |
( |
) | ( |
) | ||||
|
Net cash used in financing activities |
( |
) | ( |
) | ||||
|
Effect of exchange rate changes on cash |
( |
) | ||||||
|
Increase (decrease) in cash and cash equivalents |
( |
) | ||||||
|
Cash and cash equivalents at beginning of period |
||||||||
|
Cash and cash equivalents at end of period |
$ | $ | ||||||
|
Supplemental disclosures of cash flow information: |
||||||||
|
Cash paid for interest |
$ | $ | ||||||
|
Cash paid for income taxes, net of refunds |
$ | $ | ||||||
See accompanying notes to condensed consolidated financial statements
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
|
1. |
Basis of Presentation and Summary of Significant Accounting Policies |
Basis of Presentation and Summary of Significant Accounting Policies
The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, the “Company”) as of June 30, 2025 and for the three and six months ended June 30, 2025 and 2024, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2024, consolidated balance sheet was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of June 30, 2025, results of operations and comprehensive loss for the three and six months ended June 30, 2025 and 2024, and cash flows for the six months ended June 30, 2025 and 2024, as applicable, have been made. The results of operations for the three and six months ended June 30, 2025, are not necessarily indicative of the anticipated operating results for the full year ending December 31, 2025, or any future periods.
The accounting policies underlying the accompanying condensed consolidated financial statements are set forth in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. There have been no material changes in the Company’s significant accounting policies during the six months ended June 30, 2025.
Going Concern
The unaudited condensed consolidated financial statements for the three and six months ended June 30, 2025, have been prepared assuming that the Company will continue as a going concern. A going-concern basis assumes that the Company will continue its operations for the foreseeable future and contemplate the realization of assets and the settlement of liabilities in the normal course of business. As noted below, there is substantial doubt about the Company’s ability to continue as a going concern.
As of June 30, 2025, there was indebtedness of $
The Company continues to explore alternative sources of capital that would allow it to refinance the outstanding indebtedness due under the Credit Agreement, but its ability to access such other sources of capital is uncertain. There is no assurance that such capital will be available, be obtainable on commercially acceptable terms, or provide the Company with sufficient funds to meet its objectives. Based on its anticipated cash flows from operations, unless the Company is able to access other sources of capital or extend the date for repayment under the Credit Agreement, the Company will be unable to pay its debt obligations and fund its operations for at least twelve months from the date of issuance of the condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q. As a result, there is substantial doubt about the Company's ability to continue as a going concern.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the use of management estimates. Such estimates include the determination and establishment of certain accruals and provisions, including those for income taxes, credit losses on receivables, and defined benefit pension obligations. Estimates are also required to assess the value for inventories reported at lower of cost or net realizable value, stock-based compensation expense, and the recoverability of long-lived and intangible assets, including goodwill. On an ongoing basis, the Company assesses its previous estimates based upon currently available information. Actual results could differ materially from the estimates.
Other Operating Expenses
The components of other operating expenses for the three and six months ended June 30, 2025 and 2024 were as follows:
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
|
(in thousands) |
2025 |
2024 |
2025 |
2024 |
||||||||||||
|
Employee retention tax credit fees (see Note 5) |
$ | $ | $ | $ | ||||||||||||
|
Unclaimed property audits expense (see Note 13) |
( |
) | ||||||||||||||
|
Restructuring expenses (see Note 14) |
||||||||||||||||
|
Total other operating expenses |
$ | $ | $ | $ | ||||||||||||
Recently Issued Accounting Pronouncements Yet to Be Adopted
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax, which enhances disclosures related to the effective tax rate reconciliation, income taxes paid, as well as other disclosures. The new standard impacts footnote disclosures and is effective for the Company’s annual financial statements for the year ending December 31, 2025. The Company is continuing to assess the impact adopting ASU No. 2023-09 will have on the footnote disclosures in its consolidated financial statements.
In November 2024, the FASB issued ASU No. 2024-03, Income Statement (Subtopic 220-40): Reporting Comprehensive Income—Expense Disaggregation Disclosures, which requires enhanced disclosure of income statement expense categories to improve transparency and provide financial statement users with more detailed information about the nature, amount and timing of expenses impacting financial performance. This new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is continuing to assess the impact adopting ASU No. 2024-03 will have on the footnote disclosures in its consolidated financial statements.
|
2. |
Earnings (Loss) per Share |
Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the periods presented. The computation of diluted earnings (loss) per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive. The following table summarizes the calculation of basic and diluted net loss per share of common stock:
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
|
(in thousands, except per share data) |
2025 |
2024 |
2025 |
2024 |
||||||||||||
|
Net loss |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
Weighted average shares outstanding - basic |
||||||||||||||||
|
Dilutive effect of equity awards |
||||||||||||||||
|
Weighted average shares outstanding - diluted |
||||||||||||||||
|
Basic loss per share |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
Diluted loss per share |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
Shares excluded from diluted loss per share due to their anti-dilutive effect |
||||||||||||||||
|
3. |
Revenues |
The following tables represent a disaggregation of revenues from contracts with customers for the three and six months ended June 30, 2025 and 2024:
Revenues by type were as follows:
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
|
(in thousands) |
2025 |
2024 |
2025 |
2024 |
||||||||||||
|
Instruments, equipment, software and accessories |
$ | $ | $ | $ | ||||||||||||
|
Service, maintenance and warranty contracts |
||||||||||||||||
|
Total revenues |
$ | $ | $ | $ | ||||||||||||
Revenues by timing of recognition were as follows:
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
|
(in thousands) |
2025 |
2024 |
2025 |
2024 |
||||||||||||
|
Goods and services transferred at a point in time |
$ | $ | $ | $ | ||||||||||||
|
Goods and services transferred over time |
||||||||||||||||
|
Total revenues |
$ | $ | $ | $ | ||||||||||||
Revenues by geographic region were as follows:
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
|
(in thousands) |
2025 |
2024 |
2025 |
2024 |
||||||||||||
|
Americas |
||||||||||||||||
|
United States |
$ | $ | $ | |||||||||||||
|
Americas - Other |
||||||||||||||||
|
Europe, Middle East and Africa |
||||||||||||||||
|
Asia |
||||||||||||||||
|
China |
||||||||||||||||
|
Asia - Other |
||||||||||||||||
| $ | $ | $ | $ | |||||||||||||
Contract Liabilities
The following table provides details of contract liabilities as of the periods indicated:
|
June 30, |
December 31, |
|||||||||||||||
|
(in thousands) |
2025 |
2024 |
Change |
Percentage |
||||||||||||
|
Deferred revenue |
||||||||||||||||
|
Service, maintenance and warranty contracts |
$ | $ | $ | ( |
) | - |
% | |||||||||
|
Installation and training |
( |
) | - |
% | ||||||||||||
|
Customer advances |
( |
) | - |
% | ||||||||||||
|
Total short-term contract liabilities |
( |
) | - |
% | ||||||||||||
|
Long-term service, maintenance and warranty contracts |
% | |||||||||||||||
|
Total contract liabilities |
$ | $ | $ | ( |
) | - |
% | |||||||||
Changes in the Company’s contract liabilities are primarily due to the timing of receipt of payments under service, maintenance and warranty contracts and lower sales volumes. Additionally, customer advances have decreased due to the recognition of amounts under the Company’s exchange program, which allows customers to purchase a replacement implantable monitor of the same model at a lower price than a new monitor if the customer returns an implantable monitor to the Company after use, and returned monitor can be reprocessed and resold. During the three months ended June 30, 2025 and 2024, the Company recognized revenues of $
The following table represents the Company's remaining performance obligations from contracts that are recognized over time as of June 30, 2025:
|
Remaining Performance Obligations |
||||||||||||||||||||||||||||
|
(in thousands) |
|
Total |
||||||||||||||||||||||||||
|
Service, maintenance and warranty contracts |
$ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||
*
Provision for Expected Credit Losses on Receivables
Activity in the provision for expected credit losses on receivables was as follows:
|
Six Months Ended June 30, |
||||||||
|
(in thousands) |
2025 |
2024 |
||||||
|
Balance, beginning of period |
$ | $ | ||||||
|
Provision for expected credit losses |
( |
) | ||||||
|
Charge-offs and other |
( |
) | ( |
) | ||||
|
Balance, end of period |
$ | $ | ||||||
Concentrations
No customer accounted for more than 10% of revenues for the three and six months ended June 30, 2025 and 2024. At June 30, 2025 and December 31, 2024, no customer accounted for more than 10% of net accounts receivable.
Warranties
Activity in the product warranties accrual was as follows:
|
Six Months Ended June 30, |
||||||||
|
(in thousands) |
2025 |
2024 |
||||||
|
Balance, beginning of period |
$ | $ | ||||||
|
Provision for warranties |
||||||||
|
Warranty claims |
( |
) | ( |
) | ||||
|
Balance, end of period |
$ | $ | ||||||
|
4. |
Goodwill and Long-Lived Assets |
The Company determined that a sustained decrease in its stock price that occurred during the three months ended March 31, 2025 indicated that the carrying values of its goodwill and other long-lived assets may not be recoverable. Additional factors that contributed to this conclusion are the Company’s recent operating results, liquidity risk and the current macroeconomic conditions impacting the life sciences industry. Based on this determination, the Company performed interim quantitative impairment tests on its goodwill and other long-lived assets as of March 31, 2025 and June 30, 2025.
The recoverability of assets or an asset group to be held and used is measured by a comparison of the carrying amount of an asset or asset group to estimated undiscounted future cash flows expected to be generated by the asset or the asset group. Based on its recoverability assessment, the Company determined that there was no impairment of its other long-lived assets as of March 31, 2025 and June 30, 2025.
For the purpose of its goodwill impairment analysis, the Company has one reporting unit. The Company estimated the fair value of the reporting unit using an income-based valuation approach by means of a discounted cash flow (“DCF”) model. Under this model, the fair value of the reporting unit is determined based on the present value of estimated future cash flows, discounted at a risk-adjusted rate of return. The Company used internal forecasts and strategic long-term plans to estimate future cash flows, including projections of revenue and EBITDA, capital expenditure and working capital requirements, terminal growth rates, statutory tax rates and a market-participant discount rate. The goodwill impairment analysis also includes a reconciliation of the aggregate estimated fair value of the reporting unit to the Company’s total market capitalization. Based on this quantitative impairment analysis as of March 31, 2025, the Company determined that the carrying value of the reporting unit exceeded its fair value by $
The inputs and assumptions used in determining the fair value of the reporting unit are subjective and require management’s use of significant judgment. Certain future events and circumstances, including further deterioration of the Company’s stock price, operating results, and macroeconomic conditions, and a higher cost of capital, among others, could result in changes to these inputs and assumptions. A revision of these inputs and assumptions could cause the fair value of the reporting unit to fall further below its carrying value, resulting in additional impairment charges, which could have a material adverse effect on the Company’s results of operations.
The change in the carrying amount of goodwill for the six months ended June 30, 2025 was as follows:
|
(in thousands) |
||||
|
Carrying amount at December 31, 2024 |
$ | |||
|
Goodwill impairment |
( |
) | ||
|
Effect of change in currency translation |
||||
|
Carrying amount at June 30, 2025 |
$ |
Intangible assets, net at June 30, 2025 and December 31, 2024 consisted of the following:
|
June 30, 2025 |
December 31, 2024 |
|||||||||||||||||||||||
|
(in thousands) |
Accumulated |
Accumulated |
||||||||||||||||||||||
|
Amortizable intangible assets: |
Gross |
Amortization |
Net |
Gross |
Amortization |
Net |
||||||||||||||||||
|
Customer relationships |
$ | $ | ( |
) | $ | $ | $ | ( |
) | $ | ||||||||||||||
|
Technology and software development |
( |
) | ( |
) | ||||||||||||||||||||
|
Trade names and patents |
( |
) | ( |
) | ||||||||||||||||||||
|
Total amortizable intangible assets |
$ | $ | ( |
) | $ | $ | $ | ( |
) | $ | ||||||||||||||
|
Indefinite-lived intangible assets: |
||||||||||||||||||||||||
|
Total intangible assets |
$ | $ | ||||||||||||||||||||||
Intangible asset amortization expense for the three and six months ended June 30, 2025 and 2024 was as follows:
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
|
(in thousands) |
2025 |
2024 |
2025 |
2024 |
||||||||||||
|
Cost of revenues |
$ | $ | $ | $ | ||||||||||||
|
Operating expense |
||||||||||||||||
|
Total amortization of intangible assets |
$ | $ | $ | $ | ||||||||||||
As of June 30, 2025, estimated future amortization expense of amortizable intangible assets is as follows:
|
(in thousands) |
||||
|
2025 (remainder of year) |
$ | |||
|
2026 |
||||
|
2027 |
||||
|
2028 |
||||
|
2029 |
||||
|
Thereafter |
||||
|
Total |
$ |
|
5. |
Balance Sheet Information |
The following tables provide details of selected balance sheet items as of the periods indicated:
|
Inventories: |
June 30, |
December 31, |
||||||
|
(in thousands) |
2025 |
2024 |
||||||
|
Finished goods |
$ | $ | ||||||
|
Work in process |
||||||||
|
Raw materials |
||||||||
|
Total |
$ | $ | ||||||
|
Other Current Liabilities: |
June 30, |
December 31, |
||||||
|
(in thousands) |
2025 |
2024 |
||||||
|
Compensation |
$ | $ | ||||||
|
Customer credits |
||||||||
|
Current portion of operating lease liabilities |
||||||||
|
Employee retention tax credit funds |
||||||||
|
Professional fees |
||||||||
|
Warranty costs |
||||||||
|
Other |
||||||||
|
Total |
$ | $ | ||||||
The Coronavirus Aid, Relief, and Economic Security Act of 2020 (the “CARES Act”) provided an employee retention tax credit (“ERTC”) that was a refundable tax credit against certain employer taxes. The Company elected to account for the credit as a government grant. As there is no authoritative guidance under U.S. GAAP on accounting for grants to for-profit business entities from government entities, the Company accounts for government assistance by analogy to International Accounting Standards Topic 20, Accounting for Government Grants and Disclosure of Government Assistance (“IAS 20”). Under IAS 20, government grants are recognized when there is reasonable assurance that the grant will be received and that all conditions related to the grant will be met.
The Company received ERTC refunds of $
The Company engaged a professional services firm under a commission fee arrangement to assist with determining the Company’s eligibility to claim the ERTC refunds and accumulating the necessary support that was used as a basis in the filing. The Company paid fees of $
|
6. |
Marketable Equity Securities |
In April 2023, the Company received shares of common stock of Harvard Apparatus Regenerative Technology, Inc. (“HRGN”, formerly known as Biostage, Inc.) in connection with settlement of indemnification obligations related to litigation which was resolved during the year ended December 31, 2022.
During the six months ended June 30, 2024, the Company sold all of its remaining HRGN shares. The Company received cash proceeds of $
|
7. |
Leases |
The Company has noncancelable operating leases for offices, manufacturing facilities, warehouse space, automobiles and equipment expiring at various dates through 2030.
The components of lease expense for the three and six months ended June 30, 2025 and 2024, were as follows:
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
|
(in thousands) |
2025 |
2024 |
2025 |
2024 |
||||||||||||
|
Operating lease cost |
$ | $ | $ | $ | ||||||||||||
|
Short-term lease cost |
||||||||||||||||
|
Sublease income |
( |
) | ( |
) | ||||||||||||
|
Total lease cost |
$ | $ | $ | $ | ||||||||||||
Supplemental cash flow information related to the Company's operating leases is as follows:
|
Six Months Ended June 30, |
||||||||
|
(in thousands) |
2025 |
2024 |
||||||
|
Cash paid for amounts included in the measurement of lease liabilities |
$ | $ | ||||||
|
Right-of-use assets obtained in exchange for lease obligations |
||||||||
Supplemental balance sheet information related to the Company’s operating leases is as follows:
|
June 30, |
December 31, |
|||||||
|
(in thousands) |
2025 |
2024 |
||||||
|
Operating lease right-of-use assets |
$ | $ | ||||||
|
Current portion, operating lease liabilities |
$ | $ | ||||||
|
Operating lease liabilities, long-term |
||||||||
|
Total operating lease liabilities |
$ | $ | ||||||
|
Weighted average remaining lease term (years) |
||||||||
|
Weighted average discount rate |
% | % | ||||||
Future minimum lease payments for operating leases, with initial terms in excess of one year at June 30, 2025, are as follows:
|
Year Ending December 31, |
||||
|
(in thousands) |
||||
|
2025 (remainder of the year) |
$ | |||
|
2026 |
||||
|
2027 |
||||
|
2028 |
||||
|
2029 |
||||
|
Thereafter |
||||
|
Total lease payments |
||||
|
Less imputed interest |
( |
) | ||
|
Total operating lease liabilities |
$ |
|
8. |
Debt |
The Company’s debt, which was included within current liabilities as of June 30, 2025 and December 31, 2024, was as follows:
|
(in thousands) |
June 30, 2025 |
December 31, 2024 |
||||||
|
Term loan |
$ | $ | ||||||
|
Revolving line |
||||||||
|
Less: unamortized deferred financing costs |
( |
) | ( |
) | ||||
|
Total debt |
$ | $ | ||||||
The Company maintains the Credit Agreement with Citizens Bank, N.A., Wells Fargo Bank, National Association, and First Citizens Bank & Trust Company as the Lenders. The Credit Agreement provides for a term loan of $
Borrowings under the Credit Facility, at the option of the Company, bear interest at either (i) a rate per annum based on the Secured Overnight Financing Rate (“SOFR”) for an interest period of one, two, three or six months, plus an applicable interest rate margin determined as provided in the Credit Agreement (a “SOFR Loan”), subject to a floor of
The effective interest rate on the Company’s borrowings for the three months ended June 30, 2025 and 2024, was
The term loan required quarterly installment payments of $
The Credit Agreement includes various customary financial covenants and other affirmative and negative covenants binding on the Company. The negative covenants limit the ability of the Company, among other things, to incur debt, permit liens, make investments, sell assets, or pay dividends on its capital stock. The financial covenants include a maximum consolidated net leverage ratio and a minimum consolidated fixed charge coverage ratio. The Credit Agreement also includes customary events of default.
The March 2025 Amendment provided, among other things, that the Lenders’ commitment under the revolving credit facility would be capped at the amount outstanding thereunder as of the date thereof and thus we are unable to make additional borrowings under our revolving credit facility. The March 2025 Amendment also established certain Refinancing Milestones in connection with the Refinancing, including, by June 30, 2025, the closing of the Refinancing. The Lenders also agreed not to assert any breaches of the financial covenants included in the Credit Agreement for the first quarter of 2025 provided that the Company continued to comply with its payment obligations, achieved the Refinancing Milestones, maintained minimum liquidity (defined as the sum of (a) unrestricted cash and cash equivalents and (b) the amount by which the aggregate amount committed under the Company’s revolving credit facility exceeds the total amount drawn under the credit facility) of $3.5 million and provided the administrative agent with certain financial reports.
As of June 30, 2025, the Company was not in compliance with the Refinancing Milestones and quarterly financial covenants included in the March 2025 Amendment. On August 8, 2025, the Company entered into the August 2025 Amendment, pursuant to which the Lenders and administrative agent agreed, subject to the terms contained in the August 2025 Amendment, to waive the events of default due to the Company’s failure to achieve certain Refinancing Milestones and its failure to comply with the consolidated net leverage ratio covenant and the consolidated fixed charge coverage ratio covenant as of the June 30, 2025 test date. Pursuant to the terms of the August 2025 Amendment, the Lenders also agreed not to test the financial covenants for the fiscal quarter ended September 30, 2025, provided that the Company continues to comply with its payment obligations, maintain minimum liquidity (defined as the sum of (a) unrestricted cash and (b) the amount by which the aggregate amount committed under the Company’s revolving credit facility exceeds the total amount drawn under the credit facility) of $3.0 million and provides the administrative agent with certain financial reports. The August 2025 Amendment also added as a mandatory prepayment event the receipt of cash proceeds upon a Refinancing or upon the sale of the equity interests or all or substantially all of the assets of the Company. In addition, pursuant to the terms of the August 2025 Amendment, the applicable interest rate margin was increased such that the interest rate is equal to a rate per annum based on the SOFR plus 700 bps. In connection with the August 2025 Amendment, the Company has agreed to accomplish steps towards the Refinancing or repayment of the Credit Agreement by no later than December 5, 2025. The failure to accomplish such steps shall constitute an event of default under the Credit Agreement.
The Company agreed to pay fees of $0.4 million, or 1.00% of the outstanding debt, to the Lenders in connection with the August 2025 Amendment, of which 25% was paid upon the signing of the August 2025 Amendment and the remaining 75% will be payable upon a Refinancing or repayment of the Credit Agreement or upon the occurrence of an event of default.
|
9. |
Derivatives |
In February 2023, the Company entered into an interest rate swap contract to improve the predictability of cash flows from interest payments related to its variable, SOFR-based debt. The swap contract had a notional amount of $
The swap contract is considered an effective cash flow hedge, and as a result, net gains or losses are reported as a component of other comprehensive income (“OCI”) in the consolidated financial statements and are reclassified when the underlying hedged interest impacts earnings. An assessment is performed quarterly to evaluate the ongoing hedge effectiveness.
The following table presents the notional amount and fair value of the Company’s derivative instruments as of June 30, 2025 and December 31, 2024:
|
(in thousands) |
June 30, 2025 |
December 31, 2024 |
|||||||||||||||||
|
Derivatives Instruments |
Balance Sheet Classification |
Notional Amount |
Fair Value (a) |
Notional Amount |
Fair Value (a) |
||||||||||||||
|
Interest rate swap |
Other current liabilities |
$ | $ | ( |
) | $ | $ | ( |
) | ||||||||||
(a) See Note 10 for the fair value measurements related to these financial instruments.
The effect of the cash flow hedge on other comprehensive income (loss) and earnings for the periods presented was as follows:
|
Three Months Ended June 30, |
Six Months Ended June 30, 2025 |
|||||||||||||||
|
Derivatives Qualifying as Hedges, net of tax (in thousands) |
2025 |
2024 |
2025 |
2024 |
||||||||||||
|
Gain recognized in OCI on derivatives (effective portion) |
$ | $ | $ | $ | ||||||||||||
|
Amounts reclassified from AOCI to interest expense |
( |
) | ( |
) | ||||||||||||
|
10. |
Fair Value Measurements |
The following tables present the fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis:
|
Fair Value as of June 30, 2025 |
||||||||||||||||
|
Assets (Liabilities) (in thousands) |
Level 1 |
Level 2 |
Level 3 |
Total |
||||||||||||
|
Interest rate swap agreement |
$ | $ | ( |
) | $ | $ | ( |
) | ||||||||
|
Fair Value as of December 31, 2024 |
||||||||||||||||
|
Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||
|
Interest rate swap agreement |
$ | $ | ( |
) | $ | $ | ( |
) | ||||||||
The Company uses the market approach technique to value its financial liabilities. The fair value of the Company’s interest rate swap agreement was based on SOFR yield curves at the reporting date and is included within other current liabilities on the consolidated balance sheets at both June 30, 2025 and December 31, 2024.
|
11. |
Stock-Based Compensation |
Stock-based compensation expense for the three and six months ended June 30, 2025 and 2024 was allocated as follows:
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
|
(in thousands) |
2025 |
2024 |
2025 |
2024 |
||||||||||||
|
Cost of revenues |
$ | $ | $ | $ | ||||||||||||
|
Sales and marketing expenses |
||||||||||||||||
|
General and administrative expenses |
||||||||||||||||
|
Research and development expenses |
||||||||||||||||
|
Total stock-based compensation |
$ | $ | $ | $ | ||||||||||||
As of June 30, 2025, the total compensation costs related to unvested awards not yet recognized was $
Restricted stock unit (“RSU”) activity for the six months ended June 30, 2025 was as follows:
|
Market- |
Performance- |
|||||||||||||||||||||||
|
Time-Based |
Based |
Based |
||||||||||||||||||||||
|
Restricted |
Grant Date |
Restricted |
Grant Date |
Restricted |
Grant Date |
|||||||||||||||||||
|
Stock Units |
Fair Value |
Stock Units |
Fair Value |
Stock Units |
Fair Value |
|||||||||||||||||||
|
Balance at December 31, 2024 |
$ | $ | $ | |||||||||||||||||||||
|
Granted |
||||||||||||||||||||||||
|
Vested |
( |
) | ||||||||||||||||||||||
|
Forfeited |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
Balance at June 30, 2025 |
$ | $ | $ | |||||||||||||||||||||
The aggregate fair value of RSUs that vested during the six months ended June 30, 2025, and 2024 was $
Performance-based RSU awards are contingent on the achievement of certain performance metrics. Compensation cost associated with performance-based RSUs are recognized based on the estimated number of shares that the Company ultimately expects will be earned. If the estimated number of shares to be earned is revised in the future, then stock-based compensation expense will be adjusted accordingly.
Stock option activity for the six months ended June 30, 2025 was as follows:
|
Number of Options |
Weighted-Average Exercise Price |
Weighted-Average Remaining Contractual Term |
Aggregate Intrinsic Value (in thousands) |
|||||||||||||
|
Outstanding and exercisable at December 31, 2024 |
$ | |||||||||||||||
|
Cancelled/Forfeited |
( |
) | ||||||||||||||
|
Outstanding and exercisable at June 30, 2025 |
$ | $ | ||||||||||||||
There is aggregate intrinsic value at June 30, 2025 because the Company’s closing stock price of $
|
12. |
Income Tax |
The determination of the annual effective tax rate is based upon a number of significant estimates and judgments, including the estimated annual pretax income in each tax jurisdiction in which the Company operates and the development of tax planning strategies during the year. In addition, as a global commercial enterprise, the Company’s tax expense can be impacted by changes in tax rates or laws, the finalization of tax audits and reviews and other factors that cannot be predicted with certainty. As such, there can be significant volatility in interim tax provisions.
Income tax expense (benefit) was $
On July 4, 2025, subsequent to the end of the second quarter of fiscal 2025, the One Big Beautiful Bill Act (the “Act”) was signed into law. The Act includes several significant tax-related provisions, including the permanent extension of certain elements of the Tax Cuts and Jobs Act. The legislation features staggered effective dates beginning in 2025 and continuing through 2027. While the Company is currently evaluating the impact of the Act, including the assessment of realizability of its deferred tax assets, the Company does not expect these changes to have a significant impact on its consolidated financial statements and related disclosures. Any effects will be recorded in the period the law was enacted.
|
13. |
Commitments and Contingent Liabilities |
The Company is occasionally subject to claims and lawsuits which typically arise in the normal course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe that the outcome of any of these legal matters will have a material adverse effect on the Company’s business, results of operations, financial condition, or cash flows.
The Company is subject to unclaimed property laws in the ordinary course of its business. State escheat laws generally require entities to report and remit abandoned and unclaimed property to the state. Failure to timely report and remit the property can result in assessments that could include interest and penalties, in addition to the payment of the escheat liability itself. The Company recorded a credit of $(
|
14. |
Restructuring Costs |
On an ongoing basis, the Company reviews the global economy, the life sciences industry, and the markets in which it competes to identify operational efficiencies and align its cost base and infrastructure with customer needs and its strategic plans. In order to achieve these goals, the Company undertakes activities from time to time to optimize its business.
During the three and six months ended June 30, 2025, the Company initiated additional restructurings for which it expects to incur $
During the six months ended June 30, 2024, the Company completed a restructuring and incurred expenses of $
|
(in thousands) |
Severance |
|||
|
Balance at December 31, 2024 |
$ | |||
|
Restructuring costs |
||||
|
Cash payments |
( |
) | ||
|
Effect of change in currency translation |
||||
|
Balance at June 30, 2025 |
$ | |||
|
15. |
Segment Information |
The Company conducts business as a operating segment, which is based upon the Company’s organizational and management structure, as well as information used by the chief operating decision maker (“CODM”) to allocate resources and other factors. The key measure of segment profitability that the CODM uses to allocate resources and assess performance is consolidated net income (loss), as reported on the consolidated statements of operations. The CODM utilizes consolidated net loss by comparing actual results against budgeted amounts on a quarterly basis. The following table presents the significant revenue and expense categories of the Company’s single operating segment:
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
|
2025 |
2024 |
2025 |
2024 |
|||||||||||||
|
Revenues |
$ | $ | $ | $ | ||||||||||||
|
Less: |
||||||||||||||||
|
Cost of revenues (1) |
||||||||||||||||
|
Sales and marketing expenses (1) |
||||||||||||||||
|
General and administrative expenses (1) |
||||||||||||||||
|
Research and development expenses (1) |
||||||||||||||||
|
Amortization of acquired intangibles |
||||||||||||||||
|
Interest expense |
||||||||||||||||
|
Income tax expense (benefit) |
( |
) | ( |
) | ( |
) | ||||||||||
|
Goodwill impairment |
||||||||||||||||
|
Other segment expenses (2) |
||||||||||||||||
|
Net loss |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
(1) |
|
|
(2) |
|
Asset information provided to the CODM is consistent with that reported on the consolidated balance sheets with particular emphasis on the Company’s available liquidity, including its cash, accounts receivable, and inventory, reduced by current liabilities. Information relating to the Company’s products and services and geographical distribution of revenues is disclosed in Note 3.
|
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations. |
Forward-Looking Statements
This Quarterly Report on Form 10-Q contains statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). The forward-looking statements are principally, but not exclusively, contained in “Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about management’s confidence or expectations, and our plans, objectives, expectations, and intentions that are not historical facts. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “seek,” “expects,” “plans,” “aim,” “anticipates,” “believes,” “estimates,” “is likely,” “projects,” “forecasts,” “predicts,” “intends,” “think,” “potential,” “objectives,” “optimistic,” “strategy,” “goals,” “sees,” “new,” “guidance,” “future,” “continue,” “drive,” “growth,” “long-term,” “projects,” “develop,” “possible,” “emerging,” “opportunity,” “pursue” and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in detail in our Annual Report on Form 10-K for the year ended December 31, 2024 and our other filings with the SEC. You should carefully review all of these factors, as well as other risks described in our public filings, and you should be aware that there may be other factors, including factors of which we are not currently aware, that could cause these differences. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information. Harvard Bioscience, Inc. is referred to herein as “we,” “our,” “us,” and “the Company.”
Overview
Harvard Bioscience, Inc., a Delaware corporation, is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Our products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations (“CROs”). With operations in the United States, Europe and China, we sell through a combination of direct and distribution channels to customers around the world.
Trends and Developments
Our business is affected by global and regional economic trends and uncertainties. Our revenue has been and may continue to be affected by our customers forgoing or delaying purchases of our products and services as a result of ongoing uncertainty with respect to the level and timing of funding from the U.S. National Institutes of Health (the “NIH”) or similar government sources. Our business has also been affected by the imposition of increased tariffs on shipments of products between the United States and other countries, and in particular between the United States and China. Our revenue has been and may continue to be affected by greater restrictions and economic disincentives on international trade, including these tariffs. Products and services that we obtain from overseas sources have been and may continue to be affected by these tariffs, resulting in increased costs to our business.
If these trends are prolonged or are more severe than anticipated, our business, results of operations, and cash flow may be materially impacted.
As of June 30, 2025, the Company was not in compliance with certain refinancing milestones (the “Refinancing Milestones”) and quarterly financial covenants contained in the Company's term loan and senior revolving credit facility, dated as of December 22, 2020 (collectively, as amended, the “Credit Agreement”). On August 8, 2025, the Company entered into an amendment to the Credit Agreement (the “August 2025 Amendment”), pursuant to which the lenders party to the Credit Agreement (the “Lenders”) and the administrative agent agreed to waive the events of default due to the Company’s failure to achieve the Refinancing Milestones and its failure to comply with the consolidated net leverage ratio covenant and the consolidated fixed charge coverage ratio covenant as of the June 30, 2025 test date. See “Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources” of this report for additional information.
Selected Results of Operations
Three months ended June 30, 2025, compared to three months ended June 30, 2024
|
Three Months Ended June 30, |
||||||||||||||||
|
(dollars in thousands) |
2025 |
% of revenue |
2024 |
% of revenue |
||||||||||||
|
Revenues |
$ | 20,450 | $ | 23,097 | ||||||||||||
|
Gross profit |
11,533 | 56.4 | % | 13,218 | 57.2 | % | ||||||||||
|
Sales and marketing expenses |
4,539 | 22.2 | % | 5,395 | 23.4 | % | ||||||||||
|
General and administrative expenses |
4,262 | 20.8 | % | 5,686 | 24.6 | % | ||||||||||
|
Research and development expenses |
2,189 | 10.7 | % | 2,626 | 11.4 | % | ||||||||||
|
Amortization of intangible assets |
1,162 | 5.7 | % | 1,331 | 5.8 | % | ||||||||||
|
Other operating expenses |
200 | 1.0 | % | 249 | 1.1 | % | ||||||||||
|
Interest expense |
791 | 3.9 | % | 749 | 3.2 | % | ||||||||||
|
Loss on equity securities |
- | 0.0 | % | 281 | 1.2 | % | ||||||||||
|
Income tax expense (benefit) |
28 | 0.1 | % | (353 | ) | -1.5 | % | |||||||||
Revenues
Revenues decreased $2.6 million, or 11.5%, to $20.5 million for the three months ended June 30, 2025, compared to $23.1 million for the three months ended June 30, 2024. The decrease in revenues was primarily due to the continued softening of worldwide demand primarily from academic research institutions and CROs and impact of reciprocal tariffs.
Gross profit
Gross profit decreased $1.7 million, or 12.7%, to $11.5 million for the three months ended June 30, 2025, compared with $13.2 million for the three months ended June 30, 2024, primarily due to the decrease in revenues as well as the associated lower absorption of fixed manufacturing costs. Gross margin was 56.4% for the three months ended June 30, 2025, compared to 57.2% for the three months ending June 30, 2024. The decrease in gross margin was primarily the result of under-absorption of fixed manufacturing overhead costs due to the decrease in revenues, increases in purchase price variance as well as a higher mix of lower margin products.
Sales and marketing expenses
Sales and marketing expenses decreased $0.9 million, or 15.9%, to $4.5 million for the three months ended June 30, 2025, compared with $5.4 million for the three months ended June 30, 2024. This decrease was primarily due to reduced compensation, travel and entertainment, consulting and trade show expenses.
General and administrative expenses
General and administrative expenses decreased $1.4 million, or 25.0%, to $4.3 million for the three months ended June 30, 2025, compared with $5.7 million for the three months ended June 30, 2024. The decrease was primarily due to reduced compensation costs.
Research and development expenses
Research and development expenses decreased $0.4 million, or 16.6%, to $2.2 million for the three months ended June 30, 2025, compared with $2.6 million for the three months ended June 30, 2024. This decrease was primarily due to reduced compensation costs.
Amortization of intangible assets
Amortization of intangible assets included in operating expenses was $1.2 million for the three months ended June 30, 2025, compared with $1.3 million for the three months ended June 30, 2024.
Other operating expenses
Other operating expenses for the three months ended June 30, 2025 were $0.2 million, compared with $0.2 million for the three months ended June 30, 2024. During the three months ended June 30, 2025, other operating expenses included a fee of $0.2 million in connection with the receipt of employee retention credits. During the three months ended June 30, 2024 other operating expenses included $0.4 million of restructuring costs in connection with headcount reductions in Europe and North America, which was partially offset by a credit of $0.1 million related to closure of an unclaimed property audit.
Interest expense
Interest expense was $0.8 million for the three months ended June 30, 2025, compared with $0.7 million for the three months ended June 30, 2024.
Loss on equity securities
During the three months ended June 30, 2024, we sold all of our remaining Harvard Apparatus Regenerative Technology Inc. (“HRGN”) stock and recorded a loss on equity securities of $0.3 million. We did not hold any shares of HRGN stock during the three months ended June 30, 2025.
Income tax expense (benefit)
The income tax expense (benefit) was $0.0 million and ($0.4) million for the three months ended June 30, 2025 and 2024, respectively. The effective tax rates for the three months ended June 30, 2025 and 2024 were 1.2% and 10.8%, respectively. The lower effective tax rate during the three months ended June 30, 2025, compared to the three months ended June 30, 2024, was primarily due to the change in the mix of income by jurisdiction. The Company’s effective tax rate for the three months ended June 30, 2025, was different than the U.S. statutory rate primarily due to a Global Intangible Low-Tax Income (“GILTI”) inclusion to taxable income, and changes in valuation allowances associated with the Company’s assessment of the likelihood of the recoverability of deferred tax assets.
Six months ended June 30, 2025, compared to six months ended June 30, 2024
|
Six Months Ended June 30, |
||||||||||||||||
|
(dollars in thousands) |
2025 |
% of revenue |
2024 |
% of revenue |
||||||||||||
|
Revenues |
$ | 42,224 | $ | 47,609 | ||||||||||||
|
Gross profit |
23,717 | 56.2 | % | 27,990 | 58.8 | % | ||||||||||
|
Sales and marketing expenses |
9,510 | 22.5 | % | 11,299 | 23.7 | % | ||||||||||
|
General and administrative expenses |
9,447 | 22.4 | % | 11,649 | 24.5 | % | ||||||||||
|
Research and development expenses |
4,510 | 10.7 | % | 5,511 | 11.6 | % | ||||||||||
|
Amortization of intangible assets |
2,322 | 5.5 | % | 2,664 | 5.6 | % | ||||||||||
|
Goodwill impairment |
47,951 | 113.6 | % | - | 0.0 | % | ||||||||||
|
Other operating expenses |
464 | 1.1 | % | 1,215 | 2.6 | % | ||||||||||
|
Interest expense |
1,593 | 3.8 | % | 1,500 | 3.2 | % | ||||||||||
|
Loss on equity securities |
- | 0.0 | % | 1,593 | 3.3 | % | ||||||||||
|
Income tax benefit |
(426 | ) | -1.0 | % | (143 | ) | -0.3 | % | ||||||||
Revenues
Revenues decreased $5.4 million, or 11.3%, to $42.2 million for the six months ended June 30, 2025, compared to $47.6 million for the six months ended June 30, 2024. The decrease in revenues was primarily due to the continued softening of worldwide demand primarily from academic research institutions and CROs and impact of reciprocal tariffs.
Gross profit
Gross profit decreased $4.3 million, or 15.3%, to $23.7 million for the six months ended June 30, 2025 compared with $28.0 million for the six months ended June 30, 2024, primarily due to the decrease in revenues as well as the associated lower absorption of fixed manufacturing costs. Gross margin decreased to 56.2% for the six months ended June 30, 2025, compared with 58.8% for the six months ended June 30, 2024. The decrease in gross margin was primarily the result of under-absorption of fixed manufacturing overhead costs due to the decrease in revenues, increases in purchase price variance as well as a higher mix of lower margin products.
Sales and marketing expenses
Sales and marketing expenses decreased $1.8 million, or 15.8%, to $9.5 million for the six months ended June 30, 2025, compared with $11.3 million for the six months ended June 30, 2024. This decrease was primarily due to reduced compensation, travel and entertainment, consulting and trade show expenses.
General and administrative expenses
General and administrative expenses decreased $2.2 million, or 18.9%, to $9.4 million for the six months ended June 30, 2025, compared with $11.6 million for the six months ended June 30, 2024. The decrease was primarily due to reduced compensation costs.
Research and development expenses
Research and development expenses decreased $1.0 million, or 18.2%, to $4.5 million for the six months ended June 30, 2025, compared with $5.5 million for the six months ended June 30, 2024. This decrease was primarily due to reduced compensation costs.
Amortization of intangible assets
Amortization of intangible assets included in operating expenses decreased $0.4 million, or 12.8%, to $2.3 million for the six months ended June 30, 2025, compared with $2.7 million for the six months ended June 30, 2024.
Goodwill impairment
Goodwill impairment expenses increase by $48.0 million for the six months ended June 30, 2025. We identified a triggering event, including the sustained decrease in our stock price, our recent operating results, liquidity risk and the current macroeconomic conditions impacting the life sciences industry, requiring an interim impairment test. We recorded a non-cash goodwill impairment charge of $48.0 million in connection with the interim impairment test.
Other operating expenses
Other operating expenses decreased by $0.7 million, or 61.8% to $0.5 million for the six months ended June 30, 2025, compared to $1.2 million for the six months ended June 30, 2024. Expenses included a fee of $0.4 million in connection with the receipt of employee retention credits and restructuring costs of $0.1 million in connection with headcount reductions in Europe and North America.
Interest expense
Interest expense increased $0.1 million, or 6.2%, to $1.6 million for the six months ended June 30, 2025, compared with $1.5 million for the six months ended June 30, 2024. The increase was primarily due to higher average borrowings during the period compared to prior year.
Loss on equity securities
During the six months ended June 30, 2024, we sold all of our remaining Harvard Apparatus Regenerative Technology Inc. (“HRGN”) stock and recorded a loss on equity securities of $1.6 million. During the six months ended June 30, 2024, we sold all of our remaining HRGN shares for $1.9 million and recorded a loss of $1.6 million. We did not hold any shares of HRGN stock during the six months ended June 30, 2025.
Income tax benefit
The income tax benefit was $0.4 million and $0.1 million for the six months ended June 30, 2025 and 2024, respectively. The effective tax rates for the six months ended June 30, 2025 and 2024 were 08.% and 1.8%, respectively. The lower effective tax rate during the six months ended June 30, 2025, compared to the six months ended June 30, 2024, was primarily due to the tax effect of goodwill impairment and the release of reserves related to uncertain tax positions.
Liquidity and Capital Resources
Our primary sources of liquidity are cash and cash equivalents, internally generated cash flow from operations and our shelf registration statement that provides for the issuance of common stock, preferred stock, warrants and units up to an amount equal to $100 million. Our expected cash outlays relate primarily to cash payments due under our Credit Agreement described below as well as salaries, inventory, and capital expenditures. We held cash and cash equivalents of $7.4 million and $4.1 million as of June 30, 2025 and December 31, 2024, respectively. Borrowings outstanding were $34.9 million and $37.0 million as of June 30, 2025 and December 31, 2024, respectively.
The Coronavirus Aid, Relief, and Economic Security Act of 2020 (the “CARES Act”) provided an employee retention tax credit (“ERTC”) that was a refundable tax credit against certain employer taxes. The Company has received ERTC refunds of $5.4 million as of June 30, 2025 with $1.1 million received during the three months ended June 30, 2025. The Company’s compliance with the program’s qualifications may be subject to audit until May 2028, which is when the statute of limitation expires.
We maintain the Credit Agreement, which provides for a term loan of $40.0 million and a $25.0 million revolving credit facility with an original maturity of December 22, 2025. On March 10, 2025, we entered into an amendment to the Credit Agreement (the “March 2025 Amendment”). The March 2025 Amendment provided, among other things, that the Lenders’ commitment under our revolving credit facility would be capped at the amount outstanding thereunder as of the date thereof and thus we are unable to make additional borrowings under our revolving credit facility. The March 2025 Amendment also established certain Refinancing Milestones in connection with the refinancing of the Credit Agreement (the “Refinancing”), including receipt of a term sheet or commitment letter from one or more potential lenders, by the dates provided in the March 2025 Amendment, and the Company's consummation of the Refinancing by June 30, 2025. Pursuant to the March 2025 Amendment, the Lenders also agreed not to assert any breaches of the financial covenants included in the Credit Agreement for the first quarter of fiscal year 2025 provided that we continued to comply with our payment obligations, achieved the Refinancing Milestones, maintained minimum liquidity (defined as the sum of (a) unrestricted cash and cash equivalents and (b) the amount by which the aggregate amount committed under the Company’s revolving credit facility exceeds the total amount drawn under the credit facility) of $3.5 million and provided the administrative agent with certain financial reports. In addition, pursuant to the terms of the March 2025 Amendment the applicable interest rate margin was increased such that interest rate was equal to a rate per annum based on the Secured Overnight Financing Rate (“SOFR”) plus 400 bps and amortization payments were revised so that a proportionate payment must be made on a monthly rather than a quarterly basis.
As of June 30, 2025, we were not in compliance with the Refinancing Milestones and quarterly financial covenants contained in the March 2025 Amendment. On August 8, 2025, we entered into the August 2025 Amendment Agreement, pursuant to which the Lenders and administrative agent agreed, subject to the terms contained in the August 2025 Amendment, to waive the events of default due to the Company’s failure to achieve certain Refinancing Milestones and its failure to comply with the consolidated net leverage ratio covenant and the consolidated fixed charge coverage ratio covenant as of the June 30, 2025 test date. Pursuant to the terms of the August 2025 Amendment, the Lenders also agreed not to test the financial covenants for the fiscal quarter ended September 30, 2025, provided that the Company continues to comply with its payment obligations, maintain minimum liquidity (defined as the sum of (a) unrestricted cash and (b) the amount by which the aggregate amount committed under the Company’s revolving credit facility exceeds the total amount drawn under the credit facility) of $3.0 million and provides the administrative agent with certain financial reports. The August 2025 Amendment also added as a mandatory prepayment event the receipt of cash proceeds upon a Refinancing or upon the sale of the equity interests or all or substantially all of the assets of the Company. In addition, pursuant to the terms of the August 2025 Amendment, the applicable interest rate margin was increased such that the interest rate is equal to a rate per annum based on the SOFR plus 700 bps. In connection with the August 2025 Amendment, the Company has also agreed to accomplish steps towards the Refinancing or repayment of the Credit Agreement by no later than December 5, 2025. The failure to accomplish such steps shall constitute an event of default under the Credit Agreement. In such event, in addition to other actions the Lenders may require, the amounts outstanding under the Credit Agreement may become immediately due and payable.
The Company continues to explore alternative sources of capital that would allow it to refinance the outstanding indebtedness under the Credit Agreement, but its ability to access such other sources of capital is uncertain. There is no assurance that such capital will be available, be obtainable on commercially acceptable terms, or provide the Company with sufficient funds to meet its objectives. Based on its anticipated cash flows from operations, unless the Company is able to access other sources of capital or extend the date for repayment under the Credit Agreement, the Company will be unable to pay its debt obligations and fund its operations for at least twelve months from the date of issuance of the unaudited consolidated financial statements contained in this Quarterly Report on Form 10-Q. As a result, there is substantial doubt about the Company's ability to continue as a going concern.
CONDENSED CONSOLIDATED CASH FLOW STATEMENTS
|
Six Months Ended June 30, |
||||||||
|
(in thousands) |
2025 |
2024 |
||||||
| Net cash provided by operating activities | $ | 5,741 | $ | 557 | ||||
| Net cash (used in) provided by investing activities | (916 | ) | 233 | |||||
| Net cash used in financing activities | (2,462 | ) | (878 | ) | ||||
|
Effect of exchange rate changes on cash |
971 | (147 | ) | |||||
|
Increase (decrease) in cash and cash equivalents |
$ | 3,334 | $ | (235 | ) | |||
Net cash provided by operations was $5.7 million and $0.6 million for the six months ended June 30, 2025 and 2024, respectively. Cash flow from operations for the six months ended June 30, 2025 was positively impacted by reduction in inventories of $3.4 million and $2.2 million cash inflows from ERTC refunds received compared with the six months ended June 30, 2024.
Net cash used in investing activities was $0.9 million for the six months ended June 30, 2025 compared to cash provided by investing activities of $0.2 million for the six months ended June 30, 2024. Cash used in investing for the six months ended June 30, 2025 consisted of $0.9 million of capital expenditures for manufacturing and capitalized software development. Cash provided by investing activities for the six months ended June 30, 2024 primarily consisted of $1.9 million in proceeds from the sale of marketable equity securities, offset by $1.7 million of capital expenditures in manufacturing and information technology infrastructure and software development.
Net cash used in financing activities was $2.5 million and $0.9 million for the six months ended June 30, 2025 and 2024, respectively. During the six months ended June 30, 2025, we made $2.0 million in debt repayments on our term loan and paid $0.4 million in debt issuance costs as part of the March 2025 Amendment. During the six months ended June 30, 2024, debt outstanding under our credit facility decreased by $1.0 million, consisting of net borrowings under our revolver of $3.0 million, and payments of $4.0 million against the term loan. We also received proceeds of $0.2 million from the exercise of stock options and employee stock purchases and paid $0.1 million for taxes related to net share settlement of equity awards.
Impact of Foreign Currencies
Our international operations in some instances operate in a natural hedge, as we sell our products in many countries and a substantial portion of our revenues, costs and expenses are denominated in foreign currencies, primarily the euro and British pound.
During the three months ended June 30, 2025, changes in foreign currency exchange rates resulted in a favorable effect on revenues of $0.4 million and an unfavorable effect on expenses of $0.4 million. During the six months ended June 30, 2025, changes in foreign currency exchange rates resulted in a favorable effect on revenues of $0.2 million and an unfavorable effect on expenses of $0.3 million.
The gain (loss) associated with the translation of our foreign equity into U.S. dollars included as a component of other comprehensive loss was $2.6 million and ($0.1) million for the three months ended June 30, 2025 and 2024, respectively and $3.9 millions and ($0.9) million for the six months ended June 30, 2025 and 2024, respectively.
Currency exchange rate fluctuations included as a component of net loss resulted in currency losses of $0.4 million and $0.1 million for three months ended June 30, 2025 and 2024, respectively, and $0.6 million and $0.1 million for both the six months ended June 30, 2025 and 2024, respectively.
Critical Accounting Policies
There have been no material changes to the critical accounting policies underlying the accompanying unaudited consolidated financial statements and as set forth in Part II, Item 7 included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
Recent Accounting Pronouncements
For information on recent accounting pronouncements impacting our business, see “Recently Issued Accounting Pronouncements Yet to Be Adopted” included in Note 1 to our Condensed Consolidated Financial Statements included in Part I, Item 1. of this report.
|
Item 3. |
Quantitative and Qualitative Disclosures about Market Risk |
Not Applicable.
|
Item 4. |
Controls and Procedures. |
Evaluation of Disclosure Controls and Procedures
Under the supervision of our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2025.
Disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. As described below, we previously identified material weaknesses in our internal control over financial reporting. Solely as a result of these material weaknesses, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of June 30, 2025.
Previously Reported Material Weaknesses
As reported in Part II, Item 9A. “Controls and Procedures” of our Annual Reports on Form 10-K for the year ended December 31, 2024, we identified material weaknesses in our internal control over financial reporting related to controls over (i) our order to cash cycle and (ii) our physical count of inventories. Specifically, we did not design and maintain effective manual controls over the processing and review of a substantial portion of our revenue transactions. Additionally, we did not design and maintain an effective cycle count program to verify quantities of inventories held at Company locations that account for a substantial portion of inventories. The timeliness, level of precision, and appropriate segregation of duties in our review processes over revenue transactions and our physical counts of inventories were not sufficient to prevent, detect, and correct potential misstatements in a timely manner.
While management, with oversight from the Audit Committee of our Board of Directors, has commenced implementing changes to our internal control over financial reporting in order to remediate the control deficiencies that resulted in the material weaknesses as previously disclosed in our Form 10-K for the fiscal year ended December 31, 2024, additional time is required to complete the material weakness remediation work. We expect to continue our efforts throughout fiscal year 2025. We believe that the implementation of the remediation plans disclosed under “Part II - Item 9A - Controls and Procedures” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, will allow us to address the deficient controls within our internal control environment, which will facilitate the remediation of the material weaknesses. The material weaknesses will not be considered remediated until management completes the design and implementation of the measures disclosed under “Part II - Item 9A - Controls and Procedures” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the controls operate for a sufficient period of time such that the effectiveness of those changes is demonstrated with an appropriate amount of consistency and management has concluded, through testing, that these controls are effective. We also may conclude that additional measures may be required to remediate the material weaknesses or determine to modify the remediation plans.
Changes in Internal Control over Financial Reporting
Other than changes related to remediation of the material weaknesses, there were no changes in our internal control over financial reporting during the second quarter of fiscal 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating our controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud within the Company have been detected.
PART II. OTHER INFORMATION
|
Item 1. |
Legal Proceedings. |
The information included in Note 13 to the Condensed Consolidated Financial Statements (Unaudited) included in Part I, Item 1 of this quarterly report is incorporated herein by reference.
|
Item 1A. |
Risk Factors. |
You should carefully consider the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which could materially affect our business, financial position, or future results of operations. The risks described in our Annual Report on Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial position, or future results of operations. The risk factors set forth below updates, and should be read together with, the risk factors described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
We have substantial debt, and our lenders have waived our non-compliance with certain of the covenants in our Credit Agreement. If we fail to comply with the terms and conditions of the waiver, or if we fail to comply with covenants in our Credit Agreement in the future, the Lenders may require the amounts outstanding thereunder to become immediately due and payable.
As of June 30, 2025, there was indebtedness of $34.9 million outstanding under the Credit Agreement. As of June 30, 2025, we were not in compliance with the Refinancing Milestones and quarterly financial covenants contained in the March 2025 Amendment. Pursuant to the August 2025 Amendment, the Lenders and administrative agent agreed, subject to the terms contained in the August 2025 Amendment, to waive the Company’s events of default under the Credit Agreement. Pursuant to the terms of the August 2025 Amendment, the Lenders also agreed not to test the financial covenants for the fiscal quarter ended September 30, 2025, provided that the Company continues to comply with its payment obligations, maintain minimum liquidity (defined as the sum of (a) unrestricted cash and (b) the amount by which the aggregate amount committed under the Company’s revolving credit facility exceeds the total amount drawn under the credit facility) of $3.0 million and provides the administrative agent with certain financial reports. In connection with the August 2025 Amendment, the Company has also agreed to accomplish steps towards the Refinancing or repayment of the Credit Agreement by no later than December 5, 2025. The failure to accomplish such steps shall constitute an event of default under the Credit Agreement.
If we are not able to comply with the terms and conditions of the August 2025 Amendment, or if we are otherwise unable to maintain compliance with the covenants under the Credit Agreement, as amended, in addition to other actions the Lenders may require, the amounts outstanding under the Credit Agreement may become immediately due and payable. There can be no assurance that the Lenders will not take action to collect payment of our debt or dispose of collateral securing the debt. Our cash flow and existing capital resources may be insufficient to repay our debt, in which such case prior thereto we would have to repay, refinance and or restructure the obligations under the Credit Agreement, including with proceeds from the sale of assets, and additional equity or debt capital. If we are unsuccessful in obtaining such extension, or entering into such repayment, refinance or restructure prior to maturity or acceleration of repayment, the Lenders could foreclose against their collateral or seek other remedies, which would jeopardize our ability to continue our current operations.
We have received written notice from Nasdaq that we are not in compliance with Nasdaq’s minimum bid price requirements and if we are unable to regain compliance with Nasdaq continued listing standards, which may require effecting a reverse stock split of our common stock, we could be delisted from Nasdaq, which would negatively impact our business, our ability to raise capital, and the market price and liquidity of our common stock.
The Nasdaq Stock Market LLC (“Nasdaq”) Listing Rule 5450(a)(1) requires that securities listed on The Nasdaq Global Market maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of thirty (30) consecutive business days.
On April 4, 2025, the Company received written notice (the “Notification Letter”) from Nasdaq notifying the Company that, based on the closing bid price of the Company’s common stock for the thirty (30) consecutive business days from February 21, 2025 to April 3, 2025, the Company no longer meets the Minimum Bid Price Requirement. The Notification Letter had no immediate effect on the listing of the Company’s common stock on The Nasdaq Global Market. The Company has been provided an initial compliance period of 180 calendar days, or until October 1, 2025, to regain compliance with the Minimum Bid Price Requirement. During the compliance period, the Company’s shares of common stock will continue to be listed and traded on The Nasdaq Global Market
There is no assurance that we will be able to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at least $1.00 per share for a minimum of ten (10) consecutive business days. If the Company does not regain compliance with the Minimum Bid Price Requirement by October 1, 2025, the Company may be eligible to transfer from The Nasdaq Global Market to the Nasdaq Capital Market and seek an additional 180 calendar day compliance period. To qualify for such transfer, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the staff of Nasdaq (the “Staff”) that the Company will not be able to cure the Minimum Bid Price Requirement deficiency, or if the Company is otherwise not eligible, Nasdaq would notify the Company that its securities would be subject to delisting. In the event of such a notification, the Company may appeal the Staff’s determination to delist its securities, but there can be no assurance the Staff would grant the Company’s request for continued listing.
The Company intends to actively monitor the bid price for its common stock and will consider available options, including effecting a reverse stock split, to regain compliance with the Minimum Bid Price Requirement. Our ability to take action and the effect of any of our actions, including seeking stockholder approval for and effecting a reverse stock split, on the market price of our common stock cannot be predicted with certainty, and the history of the impact of similar measures for companies in like circumstances is varied. For example, it is possible that the per share price of the common stock after a reverse stock split will not rise in proportion to the reduction in the number of shares of the common stock outstanding resulting from the reverse stock split, effectively reducing our market capitalization, and there can be no assurance that the market price per post-reverse split share will either exceed or remain in excess of the required minimum bid price for a sustained period of time. The market price of our common stock may vary based on other factors that are unrelated to the number of shares outstanding, including the Company’s future performance.
If our common stock is delisted by Nasdaq, it could adversely affect our ability to raise additional financing through public or private sales of equity securities, could significantly affect the ability of investors to trade our securities and could negatively affect the value and liquidity of our common stock. Delisting could also have other negative impacts, including the potential loss of confidence by our employees and customers, the loss of investor and analyst interest in the Company and in our common stock and fewer business development opportunities for the Company.
|
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds. |
There were no unregistered sales of equity securities during the period covered by this report.
|
Item 3. |
Defaults Upon Senior Securities. |
None.
|
Item 4. |
Mine Safety Disclosures. |
Not applicable.
|
Item 5. |
Other Information. |
By letter dated July 17, 2025, the Nasdaq Stock Market LLC notified the Company that on July 16, 2025, as a result of the appointment of Robert Gagnon and Seth Benson to serve as members of the Board and the Audit Committee of the Board, the Company had regained compliance with Nasdaq Listing Rule 5605(c)(2)(A) relating to the composition of the Audit Committee of the Board. As of the date of this filing, the Company has not regained compliance with the Minimum Bid Price Requirement.
of our directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this report.
| Item 6. | Exhibits. |
| 10.1# | Letter Agreement between Mark Frost and the Company dated April 10, 2025 (previously filed as an exhibit to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 10, 2025 and incorporated by reference thereto). |
| 10.2# |
Harvard Bioscience, Inc. Amended and Restated 2021 Incentive Plan (previously filed as Annex A to the Proxy Statement on Schedule 14A, filed with the Securities Exchange Commission on April 21, 2025 and incorporated by reference thereto). |
|
10.3# |
Executive Employment Agreement between John Duke and the Company dated July 16, 2025 (previously filed as an exhibit to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 17, 2025 and incorporated by reference thereto). |
|
31.1 |
Certification of Chief Financial Officer of Harvard Bioscience, Inc., pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
31.2 |
Certification of Chief Executive Officer of Harvard Bioscience, Inc., pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
32.1* |
Certification of Chief Financial Officer of Harvard Bioscience, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
32.2* |
Certification of Chief Executive Officer of Harvard Bioscience, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
101.INS |
Inline XBRL Instance Document |
|
101.SCH |
Inline XBRL Taxonomy Extension Schema Document |
|
101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
|
101.DEF |
Inline XBRL Taxonomy Extension Definition Linkbase Document |
|
101.LAB |
Inline XBRL Taxonomy Extension Labels Linkbase Document |
|
101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
|
104 |
Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |
|
|
|
|
* |
This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934 |
| # | Management contract or compensatory plan or arrangement. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by undersigned thereunto duly authorized.
|
HARVARD BIOSCIENCE, INC. |
||
|
Date: August 11, 2025 |
||
|
By: |
/s/ JOHN DUKE |
|
| John Duke | ||
|
Chief Executive Officer |
||
|
By: |
/s/ MARK FROST |
|
|
Mark Frost |
||
|
Interim Chief Financial Officer |
||
